Shorter Radiation Before Surgery for Adults with Soft Tissue Sarcoma
Tests radiation given over 5 days before surgery in adults with soft tissue sarcoma.
Plain-language title generated from the registry record
Registry title: 5-Day Preoperative Radiation for Soft Tissue Sarcoma
Key facts
- Where
- Palo Alto, United StatesSee the site
- Phase
- Phase 2
Where in United States
- Stanford UniversityPalo Alto, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Stanford University
- Trial code
- NCT06087861
- Record updated
- 10 June 2026
- Original description
The purpose of this study is to examine the safety and efficacy of an abbreviated course of preoperative radiation, given over five days, for patients with soft tissue sarcoma of the extremity, trunk or retroperitoneum. This is in contrast to standard preoperative radiation, which is given over 25 days.Read full original descriptionShow less
Phase 2 5-Day Preoperative Radiation for Soft Tissue Sarcoma
The purpose of this study is to examine the safety and efficacy of an abbreviated course of preoperative radiation, given over five days, for patients with soft tissue sarcoma of the extremity, trunk or retroperitoneum. This is in contrast to standard preoperative radiation, which is given over 25 days.
Inclusion: Histologically confirmed soft tissue sarcoma of the extremity, trunk or retroperitoneum; Has been offered preoperative radiation and surgery as part of standard-of-care treatment; Age ≥ 18; KPS ≥ 70 or ECOG 0 to 2; Life expectancy ≥ 6 months; If a woman is of childbearing potential, a negative serum or urine pregnancy test must be documented; Ability to understand and the willingness to personally sign the written IRB approved informed consent document.
Exclusion: History of prior radiation to the area to be treated; Active use of other anti-cancer investigational agents; Planned use of concurrent chemotherapy, targeted therapy, or immunotherapy with radiation therapy (defined as the time interval starting 1 week before the first and last fraction of radiation therapy and surgery); Pregnancy.